4 completed, 1 terminated. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 4, Terminated 1 |
Follow odanacatib: new trials by email Literature Review of odanacatib trials Research Report on odanacatib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) in Postmenopausal Women Previously Treated With a Bisphosphonate (MK-0822-042) Odanacatib, Placebo, Vitamin D3 - Osteoporosis | Phase 2 | Completed | Merck Sharp & Dohme LLC | 246 | 2009-04-13 | 2018-08-28 |
| Efficacy and Safety of Odanacatib (MK-0822) in Participants With Involutional Osteoporosis (MK-0822-022) Odanacatib, Vitamin D3, Calcium carbonate - Osteoporosis Postmenopausal | Phase 2 | Completed | Merck Sharp & Dohme LLC | 287 | 2007-12-03 | 2018-08-27 |
| A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED) ZA, Odanacatib, Odanacatib matching placebo - Breast Cancer, Metastatic Bone Disease | Phase 2 | Completed | Merck Sharp & Dohme LLC | 43 | 2006-11-16 | 2018-08-16 |
| A 52-Week Study to Assess the Effects of MK0822 on Knee Osteoarthritis (MK-0822-011) MK0822 - Osteoarthritis | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 2 | 2006-10-01 | 2015-11-02 |
| A Study to Examine the Effects of an Experimental Drug on Postmenopausal Osteoporosis (MK-0822-004) Odanacatib, Vitamin D3, Calcium Carbonate - Osteoporosis | Phase 2 | Completed | Merck Sharp & Dohme LLC | 399 | 2005-06-24 | 2018-01-24 |
Osteoporosis (2) · Bone Diseases (1) · Breast Neoplasms (1) · Osteoarthritis (1) · Osteoporosis, Postmenopausal (1)
Chile (1) · Colombia (1) · Mexico (1) · Poland (1) · United States (1)
PMID 19874198, PMID 20740685, PMID 21147688, PMID 22777865, PMID 24064689, PMID 26879200
2008 (1)